Email updates

Keep up to date with the latest news and content from BMC Bioinformatics and BioMed Central.

This article is part of the supplement: Selected Proceedings of the 2010 AMIA Summit on Translational Bioinformatics

Open Access Proceedings

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support

Casey Lynnette Overby1*, Peter Tarczy-Hornoch123, James I Hoath4, Ira J Kalet13456 and David L Veenstra7

Author Affiliations

1 Department of Medical Education & Biomedical Informatics, University of Washington, Seattle, WA, USA

2 Department of Pediatrics, University of Washington, Seattle, WA, USA

3 Department of Computer Science & Engineering, University of Washington, Seattle, WA, USA

4 Medical Center Information Services, University of Washington, Seattle, WA, USA

5 Department of Radiation Oncology, University of Washington, Seattle, WA, USA

6 Biological Structure, University of Washington, Seattle, WA, USA

7 Department of Pharmacy, University of Washington, Seattle, WA, USA

For all author emails, please log on.

BMC Bioinformatics 2010, 11(Suppl 9):S10  doi:10.1186/1471-2105-11-S9-S10

Published: 28 October 2010

Abstract

In pursuing personalized medicine, pharmacogenomic (PGx) knowledge may help guide prescribing drugs based on a person’s genotype. Here we evaluate the feasibility of incorporating PGx knowledge, combined with clinical data, to support clinical decision-making by: 1) analyzing clinically relevant knowledge contained in PGx knowledge resources; 2) evaluating the feasibility of a rule-based framework to support formal representation of clinically relevant knowledge contained in PGx knowledge resources; and, 3) evaluating the ability of an electronic medical record/electronic health record (EMR/EHR) to provide computable forms of clinical data needed for PGx clinical decision support. Findings suggest that the PharmGKB is a good source for PGx knowledge to supplement information contained in FDA approved drug labels. Furthermore, we found that with supporting knowledge (e.g. IF age <18 THEN patient is a child), sufficient clinical data exists in University of Washington’s EMR systems to support 50% of PGx knowledge contained in drug labels that could be expressed as rules.